OncoMatch/Clinical Trials/NCT05769725
A Study to Evaluate Serplulimab in Combination With Docetaxel +S-1 VS. Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage IIIc Gastric Cancer
Is NCT05769725 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Serplulimab and Docetaxel for serplulimab,gastric cancer, adjuvant therapy.
Treatment: Serplulimab · Docetaxel · S1 — To evaluate the efficacy and safety of Serplulimab in Combination With Docetaxel +S-1 vs. Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage IIIc Gastric Cancer (PD-L1 + / MSI-H / EBV +/dMMR) . Secondary study objective: To observe and evaluate the overall survival and adverse events of Serplulimab in Combination With Docetaxel +S-1 vs. Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage IIIc Gastric Cancer (PD-L1+ / MSI-H / EBV +/dMMR). To evaluate the safety of Serplulimab in Combination With Docetaxel +S-1 vs. Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage IIIc Gastric Cancer (PD-L1 + / MSI-H / EBV +/dMMR). To explore the incidence of PD-L1 + / MSI-H / EBV + /dMMR in stage IIIc gastric cancer. To explore the correlation of PD-L1 + / MSI-H / EBV + /dMMR in stage IIIc gastric cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Gastric Cancer
Biomarker criteria
Required: PD-L1 (CD274) overexpression (CPS ≥ 5)
PD-L1 + CPS ≥ 5
Required: MSH2 deficient mismatch repair
dMMR
Required: MSH6 deficient mismatch repair
dMMR
Required: MLH1 deficient mismatch repair
dMMR
Required: PMS2 deficient mismatch repair
dMMR
Required: MSI MSI-H
MSI-H +
Required: EBV positive
EBV+
Disease stage
Required: Stage III
Excluded: Stage DISTANT METASTASIS
Stage III gastric cancer confirmed by pathology; Distant metastasis was diagnosed by CT /MR/ EUS [excluded]
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
No preoperative anti-tumor treatment for gastric cancer, including chemotherapy and local treatment
Cannot have received: radiotherapy
No preoperative anti-tumor treatment for gastric cancer, including chemotherapy and local treatment
Cannot have received: immunotherapy
No preoperative anti-tumor treatment for gastric cancer, including chemotherapy and local treatment
Lab requirements
Blood counts
hemoglobin ≥ 90g/L; absolute neutrophil count ≥ 1.5 × 10^9/L; platelet count ≥ 100 × 10^9/L
Liver function
AST or ALT ≤ 2.5 ULN; ALP ≤ 2.5×ULN
The baseline blood routine and biochemical indexes of the selected patients should meet the following standards: hemoglobin ≥ 90g / L; absolute neutrophil count ≥ 1.5 × 10^9 / L; platelet count ≥ 100 × 10^9 / L; AST or ALT ≤ 2.5 ULN; ALP ≤ 2.5×ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify